Onward Medical has announced the establishment of a Level 1 American Depositary Receipt (ADR) program to enhance its accessibility for U.S. investors. The ADRs, which began trading on the OTCQX market under the ticker “ONWRY,” represent foreign shares in U.S. dollar-denominated instruments, making it easier for U.S. investors to buy, hold, and sell shares of the company.
The move aims to increase Onward’s stock liquidity and broaden its shareholder base, with the ADR program expected to appeal to U.S. institutional investors who prefer to transact in U.S. dollars and trade on U.S. platforms. Onward, based in Eindhoven, The Netherlands, is developing implantable technologies for neurological conditions and chronic pain, including a spinal cord stimulation system for Parkinson’s disease and brain-computer interface (BCI) technology.
Follow MEDWIRE.AI for more updates on medical technology and investment opportunities.
